Karam C. Mounzer, MD
Clinical Professor of Medicine (Infectious Diseases)
Attending Physician, Penn Presbyterian Medical Center
Department: Medicine
Contact information
Philadelphia Fight
1233 Locust Street
Philadelphia, PA 19107
1233 Locust Street
Philadelphia, PA 19107
Office: 215-790-1788
Fax: 215-732-5490
Fax: 215-732-5490
Email:
mounzerk@fight.org
mounzerk@fight.org
Education:
Bachelor (Experimental Sciences and French Literature)
College Notre Dame de Jamhour, Beirut, Lebanon, 1985.
MD (Pre-Med & Med combined)
Saint Joseph University, Faculty of Medicine, Beirut, Lebanon , 1992.
Permanent linkBachelor (Experimental Sciences and French Literature)
College Notre Dame de Jamhour, Beirut, Lebanon, 1985.
MD (Pre-Med & Med combined)
Saint Joseph University, Faculty of Medicine, Beirut, Lebanon , 1992.
Description of Research Expertise
Clinical Development of new antiretroviral agentsDescription of Clinical Expertise
Treatment of Multi drug Resistant HIV virus, HIV-HCV co-infectionDescription of Other Expertise
Suboxone Clinic for HIV infected opioid-addicted patientsSelected Publications
Maguire C, Rueve K, Farmer E, Huesgen E, Karaj A, Binkley A, Mounzer K, Brizzi M, Chary P, Sung P, Graziani A, Hiserodt E, Baron J, Koenig H, Short WR: Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine. Clin Infect Dis Aug 2025.McMyn NF, Varriale J, Wu HWS, Hariharan V, Moskovljevic M, Tan TS, Lai J, Singhal A, Lynn K, Mounzer K, Tebas P, Montaner LJ, Hoh R, Yu XG, Lichterfeld M, Simonetti FR, Kovacs C, Deeks SG, Siliciano JM, Siliciano RF: Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies. J Clin Invest Jul 2025.
Mounzer K, Osterman MD, Brunet L, Hsu RK, Pierone G Jr, Fusco JS, Prata Menezes N, Gruber J, Lim T, Dunbar M, Fusco GP: Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide. AIDS Res Ther Jul 2025.
Pozniak A, Orkin C, Yazdanpanah Y, Baumgarten A, Mounzer K, D'Antoni ML, Huang H, Liu H, Andreatta K, VanderVeen LA, Callebaut C, Hindman JT, Arribas JR: Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV. Infect Dis Ther JUN 2025.
Mounzer K, Brunet L, Sension M, Hsu RK, Osterman MD, Fusco JS, Whiteside YO, Fusco GP: Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study. AIDS Res Ther JUN 2025.
Mohammed Zogheib, John Koethe, Jordan E. Lake, Karam Mounzer, Christian Caldji, Brandon Cash, Colleen McGary: BMI Is a Poor Surrogate for Excess Visceral Adiposity and Cardiovascular Risk in Persons With HIV. CROI 2025 May 2025.
Richard K, Yuan Z, Tang H-Y, Goldman AR, Kuthu R, Raphane B, Register ET, Sharma P, Ross BN, Morris J, Williams DE, Cheney C, Wu G, Mounzer K, Laird GM, Zuck P, Andersen RJ, Simonambango S, Andrae-Marobela K, Tietjen I, Montaner LJ: Ex vivo and in vivo HIV-1 latency reversal by "Mukungulu," a protein kinase C-activating African medicinal plant extract. mBio. May 2025.
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S: Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clin Infect Dis Apr 2025.
Karam Mounzer,Laurence Brunet, Ricky K. Hsu, Philip C. Lackey, Michael Sension, Michael B. Wohlfeiler, Joshua Gruber, Megan S. Dunbar, Seojin Park, Jennifer S. Fusco, Gregory P. Fusco: First Year of Lenacapavir Long-Acting Injectable Use in the OPERA Cohort. CROI 2025.
Malcolm Hedgcock, pedro.cahn, Mounzer, Karam, Peter Sklar, Mauricio Montezuma , Nicolas Margot , Xu Zhang , Chloe Orkin : Demographic and clinical characteristics of Phase 3 participants in ARTISTRY-1, an open-label study comparing a bictegravir/lenacapavir (BIC/LEN) single tablet regimen (STR) with complex antiretroviral therapy (ART) regimens. EACS 2025.